Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 244

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”

Filippi, M., Rovaris, M., Rocca, M. A., Sormani, M. P., Wolinsky, J. S., Comi, G., the European/Canadian Glatiramer Acetate Study Group*·2001·Neurology

Abstract

The authors evaluated whether glatiramer acetate (GA) modifies the severity of tissue damage in 1,722 new lesions from 239 patients with MS enrolled in a placebo-controlled trial monitored with monthly cerebral MRI. The percentage of new lesions that evolved into "black holes" was lower in GA-treated than in placebo patients on scans at 7 (18.9 and 26.3%; p = 0.04) and 8 (15.6 and 31.4%; p = 0.002) months after lesion appearance. GA has a favorable effect on tissue disruption in MS lesions once they are formed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.57.4.731

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 244

Metadata

Authors
Filippi, M., Rovaris, M., Rocca, M. A., Sormani, M. P., Wolinsky, J. S., Comi, G., & the European/Canadian Glatiramer Acetate Study Group*
Venue
Neurology
Published
2001-08-28
Volume
57
Issue
4
Pages
731-733
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W1967733776
Cited by
244
References
2
FWCI
9.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. https://app.cochat.ai/papers/10.1212/wnl.57.4.731
The paper
Filippi, M., Rovaris, M., Rocca, M. A., Sormani, M. P., Wolinsky, J. S., Comi, G., & the European/Canadian Glatiramer Acetate Study Group*. (2001). Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology. https://doi.org/10.1212/wnl.57.4.731

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.